Table 2. Multivariable analysis of factors associated with diagnostic and treatment delay of rifampicin-resistant TB patients.
| Variable | Diagnostic delay (n = 201) | Treatment delay (n = 339) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | OR | 95% CI | AOR | 95% CI | n (%) | OR | 95% CI | AOR | 95% CI | |
| Male | 57 (49.6%) | 1.2 | 0.7–2.2 | 1.1 | 0.6–1.9 | 138 (71.5%) | 0.8 | 0.5–1.4 | 0.8 | 0.5–1.3 |
| Age (years) | 38.5±13.5 | 1.0 | 0.9–1.0 | 1.0 | 0.9–1.0 | 38.6±12.5 | 1.0 | 0.9–1.0 | 1.0 | 0.9–1.0 |
| Residence: | ||||||||||
| Bandung | 19 (30.6%) | Reference | Reference | 70 (64.8%) | Reference | Reference | ||||
| Outside Bandung | 76 (54.7%) | 2.7 | 1.4–5.1** | 2.7 | 1.5–5.2** | 177 (76.6%) | 1.8 | 1.1–2.9 | 2.0 | 1.2–3.4** |
| Monthly household income: | ||||||||||
| Do not have income | 44 (46.8%) | Reference | Reference | Reference | Reference | |||||
| < 74 USD | 15 (48.4%) | 1.1 | 0.5–2.4 | 0.9 | 0.4–2.1 | 24 (68.6%) | 0.8 | 0.4–1.8 | 0.8 | 0.3–1.8 |
| 74–148 USD | 21 (44.7%) | 0.9 | 0.5–1.9 | 0.8 | 0.4–1.8 | 54 (67.5%) | 0.8 | 0.4–1.4 | 0.7 | 0.4–1.3 |
| >148 USD | 15 (51.7%) | 1.2 | 0.5–2.8 | 1.3 | 0.5–3.1 | 42 (85.7%) | 2.3 | 0.9–5.4 | 2.5 | 1.0–6.0 |
| Presumptive MDR-TB criteria: | ||||||||||
| Treatment failure | 65 (48.5%) | 1.2 | 0.6–2.1 | 1.2 | 0.7–2.2 | 138 (75%) | 1.3 | 0.8–2.0 | 1.3 | 0.8–2.1 |
| Other criteria* | 30 (44.8%) | Reference | Reference | 109 (70.3%) | Reference | Reference | ||||
| Frequency of previous TB treatment: | ||||||||||
| ≤ 2 times | 68 (44.7%) | Reference | Reference | 188 (71.5%) | Reference | Reference | ||||
| > 2 times | 27 (55.1%) | 1.5 | 0.8–2.9 | 1.3 | 0.7–2.6 | 59 (77.6%) | 1.4 | 0.8–2.5 | 1.3 | 0.7–2.5 |
OR: odds ratio; AOR: adjusted odds ratio.
*Other criteria: default, relapse, contact history with MDR-TB patients, TB-HIV co-infection and history/current use of insufficient treatment regimen.
**p<0.05.